If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 2002 Ph.D. National Taiwan University
  • 1994 M.S. Taipei Medical University

Experience

  • 2019- Director, Ph.D Program in Biotechnology Research and Development, Taipei Medical University
  • 2018- Professor, Master Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University
  • 2016-2018 Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
  • 2013-2016 Associate Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
  • 2008-2013 Assistant Professor, Department of Pharmacology, Taipei Medical University
  • 2009-2013 Assistant Investigator, National Health Research Institutes
  • 2007-2009 Assistant Investigator, National Taiwan University
  • 2002-2007 Postdoctor, National Taiwan Universiy
  • 1994-1998 Teaching Assistant, Chang-Gung University

Research Interests

  • Drug Discovery
  • Disease animal model
  • Pharmacology

URL

Awards

  • 2019 Single Research Project Budget Award, Taipei Medical University

Fingerprint Dive into the research topics where Shiow-Lin Pan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 16 Similar Profiles
Apoptosis Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Histone Deacetylase Inhibitors Medicine & Life Sciences
Cells Chemical Compounds
Smooth Muscle Myocytes Medicine & Life Sciences
Growth Medicine & Life Sciences
Heterografts Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2020

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(2/3)

Pan, S.

8/1/197/1/20

Project: A - Government Institutionb - Ministry of Science and Technology

選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究(II)

Pan, S.

5/1/1910/1/19

Project: A - Government Institutionb - Ministry of Science and Technology

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(1/3)

Pan, S.

8/1/187/1/19

Project: A - Government Institutionb - Ministry of Science and Technology

選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究

Pan, S.

12/1/1710/31/18

Project: A - Government Institutionb - Ministry of Science and Technology

選擇性HDAC1及2抑制劑作為新穎性抗癌藥物之藥物開發與藥理機轉探討

Pan, S.

8/1/177/31/18

Project: A - Government Institutionb - Ministry of Science and Technology

Research Output 1996 2020

  • 2976 Citations
  • 33 h-Index
  • 129 Article
1 Citation (Scopus)

N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression

Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., Jan 1 2020, In : European Journal of Medicinal Chemistry. 185, p. 111725 111725.

Research output: Contribution to journalArticle

Anilides
HSP90 Heat-Shock Proteins
Histone Deacetylase Inhibitors
Histone Deacetylases
Down-Regulation
Growth Inhibitors
Amides
Prostatic Neoplasms
Cells
Lead compounds
3 Citations (Scopus)

Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo

Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., Jun 1 2019, In : Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Histone Deacetylase Inhibitors
Breast Neoplasms
Histone Deacetylases
Acetylation
1 Citation (Scopus)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Chao, M. W., Chang, L. H., Tu, H. J., Chang, C. D., Lai, M. J., Chen, Y. Y., Liou, J. P., Teng, C. M. & Pan, S. L., May 29 2019, In : Clinical Epigenetics. 11, 1, 85.

Research output: Contribution to journalArticle

Open Access
Histone Deacetylase Inhibitors
Mitogen-Activated Protein Kinase Kinases
Pancreatic Neoplasms
Epidermal Growth Factor Receptor
Heterografts
1 Citation (Scopus)

MPT0G413, A novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells

Huang, F. I., Wu, Y. W., Sung, T. Y., Liou, J. P., Lin, M. H., Pan, S. L. & Yang, C. R., Jan 1 2019, In : Frontiers in Oncology. 9, APR, p. 249 249.

Research output: Contribution to journalArticle

Open Access
Histone Deacetylases
Multiple Myeloma
Neoplasms
Histone Deacetylase Inhibitors
Growth